TAP to showcase ambr system at Cell Line Development and Engineering 2010

The Automation Partnership (TAP), a world leader in the design and development of innovative automation for life science applications, is pleased to announce it will be showcasing its new advanced micro bioreactor system (ambr™) at Cell Line Development and Engineering 2010, February 25-26 in San Francisco, USA.

“We look forward to discussing our exciting proof-of concept data with bioprocess scientists looking for intelligent, new approaches to improve their cell line selection and process development.”

ambr replicates the characteristics of classical bioreactors at microscale (10 – 15 ml working volume), by using cost effective, disposable micro bioreactors controlled by an automated workstation. It enables the rapid evaluation of multiple bioreactor cultures (24 in parallel), improving productivity in cell line development with significant savings on materials and labour.

During the conference Dr Richard Wales, TAP’s Technology Director for ambr, will be presenting exciting data from independent trials of CHO cells expressing an antibody construct. This includes data from testing carried out at major biotechnology companies, with comparison to both 5 and 10 litre bioreactors, and demonstrates the potential of ambr as a new, cost-effective route for cell line selection and early process development.

European scientists, who want to find out about ambr’s capabilities but are not attending this show, will be pleased to know the system is also being premiered just a week later at Cell Line Development and Engineering 2010 on March 1-5, in Prague, Czech Republic.

Dr Richard Wales stated:” The infrastructure requirements, overheads and labour costs of working with bench-scale bioreactors limits their use in many organisations. We are delighted to have developed a solution to this problem that not only saves time by automating set-up, sampling and maintenance of 24 individual disposable bioreactors, but also really mimics the physical characteristics of a classical bioreactor.”

Dr Wales added: “We look forward to discussing our exciting proof-of concept data with bioprocess scientists looking for intelligent, new approaches to improve their cell line selection and process development.”